Liberty Biopharma (LTY) Stock Price, News & Analysis

Company Overview

Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.

Key Stats

• Today's Range: C$2.00 to C$2.00
• 50-Day Range: C$2.00 to C$2.00
• 52-Week Range: C$0.06 to C$2.74
• Volume: 700 shs
• Average Volume: 23,286 shs
• Market Capitalization: C$21.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LTY Stock Analysis - Frequently Asked Questions

How have LTY shares performed this year?

Liberty Biopharma's stock was trading at C$2.00 at the beginning of the year. Since then, LTY shares have increased by 0.0% and is now trading at C$2.00.
View the best growth stocks for 2024 here.

How do I buy shares of Liberty Biopharma?

Shares of LTY stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Liberty Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Liberty Biopharma investors own include Barrick Gold (GOLD), Aecon Group (AEGXF), Adial Pharmaceuticals (ADIL), Adeia (ADEA), Acurx Pharmaceuticals (ACXP), AC Immune (ACIU) and Air Canada (AC).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:LTY
• Previous Symbol: CVE:VVA
• CUSIP: N/A
• CIK: N/A
• Web: www.libertybiopharma.com
• Phone: +1-604-3777575
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 8.19
• Current Ratio: 0.12
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 2,000.00
• Book Value: C$0.79 per share
• Price / Book: 2.53

Miscellaneous

• Outstanding Shares: 10,770,000
• Free Float: N/A
• Market Cap: C$21.54 million
• Optionable: Not Optionable
• Beta: N/A